{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:43:38Z","timestamp":1792176218344,"version":"4.4.0"},"reference-count":108,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2020,10,31]]},"DOI":"10.5582\/irdr.2020.03054","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T22:05:24Z","timestamp":1594245924000},"page":"187-195","source":"Crossref","is-referenced-by-count":20,"title":["Acute intermittent porphyria: focus on possible mechanisms of acute and chronic manifestations"],"prefix":"10.5582","volume":"9","author":[{"given":"Yuelin","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Endocrinology, The second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of First Clinical Medical College, Southern Medical University, Guangzhou, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songyun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bronisch O, Stauch T, Haverkamp T, Beykirch MK, Petrides PE. Acute porphyrias: a German monocentric study of the biochemical, molecular genetic, and clinical data of 62 families. Ann Hematol. 2019; 98:2683-2691.","DOI":"10.1007\/s00277-019-03831-7"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Duque-Serrano L, Patarroyo-Rodriguez L, Gotlib D, Molano-Eslava JC. Psychiatric aspects of acute porphyria: a comprehensive review. Curr Psychiatry Rep. 2018; 20:5.","DOI":"10.1007\/s11920-018-0867-1"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Yasuda M, Gan L, Chen B, Yu C, Zhang J, Gama-Sosa MA, Pollak DD, Berger S, Phillips JD, Edelmann W, Desnick RJ. Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria. Hum Mol Genet. 2019; 28:1755-1767.","DOI":"10.1093\/hmg\/ddz003"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Neeleman RA, Wagenmakers MAEM, Koole-Lesuis RH, Mijnhout GS, Wilson JHP, Friesema ECH, Langendonk JG. Medical and financial burden of acute intermittent porphyria. J Inherit Metab Dis. 2018; 41:809-817.","DOI":"10.1007\/s10545-018-0178-z"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Stein PE, Badminton MN, Rees DC. Update review of the acute porphyrias. Br J Haematol. 2017; 176:527-538.","DOI":"10.1111\/bjh.14459"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Spiritos Z, Salvador S, Mosquera D, Wilder J. Acute intermittent porphyria: current perspectives and case presentation. Ther Clin Risk Manag. 2019; 15:1443-1451.","DOI":"10.2147\/TCRM.S180161"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Szlendak U, Bykowska K, Lipniacka A. Clinical, biochemical and molecular characteristics of the main types of porphyria. Adv Clin Exp Med. 2016; 25:361-368.","DOI":"10.17219\/acem\/58955"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. St\u00f6lzel U, Doss MO, Schuppan D. Clinical guide and update on porphyrias. Gastroenterology. 2019; 157:365-381 e4.","DOI":"10.1053\/j.gastro.2019.04.050"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Barman-Aks\u00f6zen J, Suter L, Wegmann F, Meienberg J, Minder AE, Beer M, Komminoth P, Minder EI, Schneider-Yin X. A next-generation-sequencing panel for mutational analysis of dominant acute hepatic porphyrias. Scand J Clin Lab Invest. 2019; 79:305-313.","DOI":"10.1080\/00365513.2019.1622030"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Jaramillo-Calle DA, Solano JM, Rabinstein AA, Bonkovsky HL. Porphyria-induced posterior reversible encephalopathy syndrome and central nervous system dysfunction. Mol Genet Metab. 2019; 128:242-253.","DOI":"10.1016\/j.ymgme.2019.10.011"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Bonkovsky HL, Dixon N, Rudnick S. Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs). Mol Genet Metab. 2019; 128:213-218.","DOI":"10.1016\/j.ymgme.2019.03.002"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Zheng X, Liu X, Wang Y, Zhao R, Qu L, Pei H, Tuo M, Zhang Y, Song Y, Ji X, Li H, Tang L, Yin X. Acute intermittent porphyria presenting with seizures and posterior reversible encephalopathy syndrome: Two case reports and a literature review. Medicine (Baltimore). 2018; 97:e11665.","DOI":"10.1097\/MD.0000000000011665"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Shen J, O&apos;Keefe K, Webb LB, DeGirolamo A. Acute porphyria in a patient with Arnold Chiari malformation. Am J Case Rep. 2015; 16:99-103.","DOI":"10.12659\/AJCR.891079"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Wang B, Rudnick S, Cengia B, Bonkovsky HL. Acute hepatic porphyrias: review and recent progress. Hepatol Commun. 2019; 3:193-206.","DOI":"10.1002\/hep4.1297"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Arora S, Young S, Kodali S, Singal AK. Hepatic porphyria: a narrative review. Indian J Gastroenterol. 2016; 35:405-418.","DOI":"10.1007\/s12664-016-0698-0"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Meyer UA, Schuurmans MM, Lindberg RL. Acute porphyrias:pathogenesis of neurological manifestations. Semin Liver Dis. 1998; 18:43-52.","DOI":"10.1055\/s-2007-1007139"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Lutz P, Maring D, Tschampa HJ, Sauerbruch T. A 25-year-old patient with colonic pseudo-obstruction, hyponatremia, hypertension, and diffuse pain. Med Klin (Munich). 2010; 105:267-272.","DOI":"10.1007\/s00063-010-1047-1"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Herrick AL, McColl KE. Acute intermittent porphyria. Best Pract Res Clin Gastroenterol. 2005; 19:235-249.","DOI":"10.1016\/j.bpg.2004.10.006"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Anyaegbu E, Goodman M, Ahn SY, Thangarajh M, Wong M, Shinawi M. Acute intermittent porphyria: a diagnostic challenge. J Child Neurol. 2012; 27:917-921.","DOI":"10.1177\/0883073811427603"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ren Y, Xu LX, Liu YF, Xiang CY, Gao F, Wang Y, Bai T, Yin JH, Zhao YL, Yang J. A novel 55-basepair deletion of hydroxymethylbilane synthase gene found in a Chinese patient with acute intermittent porphyria and her family: a case report. Medicine (Baltimore). 2018; 97:e12295.","DOI":"10.1097\/MD.0000000000012295"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Dagens A, Gilhooley MJ. Acute intermittent porphyria leading to posterior reversible encephalopathy syndrome (PRES): a rare cause of abdominal pain and seizures. BMJ Case Rep. 2016.","DOI":"10.1136\/bcr-2016-215350"},{"key":"22","unstructured":"22. Mungan N\u00d6, Yilmaz BS, Nazoglu S, Yildizdas D, Herg\u00fcner \u00d6, Turgut M, \u00d6ktem M. A 17-year-old girl with chronic intermittent abdominal pain. Acute intermittent porphyria. Pediatr Ann. 2015; 44:139-141."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Bylesj\u00f6 I, Forsgren L, Lithner F, Boman K. Epidemiology and clinical characteristics of seizures in patients with acute intermittent porphyria. Epilepsia. 1996; 37:230-235.","DOI":"10.1111\/j.1528-1157.1996.tb00018.x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Malinzak EB, Knudsen NW, Udani AD, Vikraman D, Sudan DL, Miller TE. Perioperative challenges in liver transplantation for a patient with acute intermittent porphyria. J Cardiothorac Vasc Anesth. 2018; 32:2716-2720.","DOI":"10.1053\/j.jvca.2017.11.045"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kumar B. Acute intermittent porphyria presenting solely with psychosis: a case report and discussion. Psychosomatics. 2012; 53:494-498.","DOI":"10.1016\/j.psym.2012.03.008"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. O&apos;Malley R, Rao G, Stein P, Bandmann O. Porphyria: often discussed but too often missed. Pract Neurol. 2018; 18:352-358.","DOI":"10.1136\/practneurol-2017-001878"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Balwani M, Singh P, Seth A, Debnath EM, Naik H, Doheny D, Chen B, Yasuda M, Desnick RJ. Acute intermittent porphyria in children: a case report and review of the literature. Mol Genet Metab. 2016; 119:295-299.","DOI":"10.1016\/j.ymgme.2016.10.005"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. New GH, Hsu PY, Wu MH. Acute intermittent porphyria exacerbation following in vitro fertilization treatment. Taiwan J Obstet Gynecol. 2016; 55:281-284.","DOI":"10.1016\/j.tjog.2015.08.025"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Gu\u00e9niat J, Delpont B, Garnier L, Aidan M, Giroud M, B\u00e9jot Y. Posterior reversible encephalopathy syndrome revealing acute intermittent porphyria. Rev Neurol (Paris). 2016; 172:402-403.","DOI":"10.1016\/j.neurol.2016.06.002"},{"key":"30","doi-asserted-by":"crossref","unstructured":"31. Pierach CA, Edwards PS. Neurotoxicity of delta-aminolevulinic acid and porphobilinogen. Exp Neurol. 1978; 62:810-814.","DOI":"10.1016\/0014-4886(78)90287-X"},{"key":"31","doi-asserted-by":"crossref","unstructured":"32. Helson L, Braverman S, Mangiardi J. Delta-aminolevulinic acid effects on neuronal and glial tumor cell lines. Neurochem Res. 1993; 18:1255-1258.","DOI":"10.1007\/BF00975044"},{"key":"32","doi-asserted-by":"crossref","unstructured":"33. Bonkowsky HL, Schady W. Neurologic manifestations of acute porphyria. Semin Liver Dis. 1982; 2:108-124.","DOI":"10.1055\/s-2008-1040701"},{"key":"33","doi-asserted-by":"crossref","unstructured":"34. Tracy JA, Dyck PJ. Porphyria and its neurologic manifestations. Handb Clin Neurol. 2014; 120:839-849.","DOI":"10.1016\/B978-0-7020-4087-0.00056-5"},{"key":"34","doi-asserted-by":"crossref","unstructured":"35. Roth C, Ferbert A. The posterior reversible encephalopathy syndrome: what&apos;s certain, what&apos;s new?. Pract Neurol. 2011; 11:136-144.","DOI":"10.1136\/practneurol-2011-000010"},{"key":"35","doi-asserted-by":"crossref","unstructured":"36. Gao B, Lyu C, Lerner A, McKinney AM. Controversy of posterior reversible encephalopathy syndrome: what have we learnt in the last 20 years?. J Neurol Neurosurg Psychiatry. 2018; 89:14-20.","DOI":"10.1136\/jnnp-2017-316225"},{"key":"36","doi-asserted-by":"crossref","unstructured":"37. Chen Z, Shen GQ, Lerner A, Gao B. Immune system activation in the pathogenesis of posterior reversible encephalopathy syndrome. Brain Res Bull. 2017; 131:93-99.","DOI":"10.1016\/j.brainresbull.2017.03.012"},{"key":"37","doi-asserted-by":"crossref","unstructured":"38. Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015; 14: 914-925.","DOI":"10.1016\/S1474-4422(15)00111-8"},{"key":"38","doi-asserted-by":"crossref","unstructured":"39. Suarez JI, Cohen ML, Larkin J, Kernich CA, Hricik DE, Daroff RB. Acute intermittent porphyria: clinicopathologic correlation. Report of a case and review of the literature. Neurology. 1997; 48:1678-1683.","DOI":"10.1212\/WNL.48.6.1678"},{"key":"39","doi-asserted-by":"crossref","unstructured":"40. Takata T, Kume K, Kokudo Y, Ikeda K, Kamada M, Touge T, Deguchi K, Masaki T. Acute intermittent porphyria presenting with posterior reversible encephalopathy syndrome, accompanied by prolonged vasoconstriction. Intern Med. 2017; 56:713-717.","DOI":"10.2169\/internalmedicine.56.7654"},{"key":"40","doi-asserted-by":"crossref","unstructured":"41. Suh Y, Gandhi J, Seyam O, Jiang W, Joshi G, Smith NL, Ali Khan S. Neurological and neuropsychiatric manifestations of porphyria. Int J Neurosci. 2019; 129:1226-1233.","DOI":"10.1080\/00207454.2019.1655014"},{"key":"41","doi-asserted-by":"crossref","unstructured":"42. Sassa S. Diagnosis and therapy of acute intermittent porphyria. Blood Rev. 1996; 10:53-58.","DOI":"10.1016\/S0268-960X(96)90020-X"},{"key":"42","doi-asserted-by":"crossref","unstructured":"43. Ramanujam VS, Anderson KE. Porphyria diagnostics-part 1: a brief overview of the porphyrias. Curr Protoc Hum Genet. 2015; 86:17.20.1-17.20.26.","DOI":"10.1002\/0471142905.hg1720s86"},{"key":"43","doi-asserted-by":"crossref","unstructured":"44. Bonnefoy Mirralles AM, Torres-Castro R, Ovalle Guzman C. A comprehensive rehabilitation program and follow-up assessment for acute intermittent porphyria. Am J Phys Med Rehabil. 2017; 96:e85-e88.","DOI":"10.1097\/PHM.0000000000000590"},{"key":"44","doi-asserted-by":"crossref","unstructured":"45. Demily C, Sedel F. Psychiatric manifestations of treatable hereditary metabolic disorders in adults. Ann Gen Psychiatry. 2014; 13:27.","DOI":"10.1186\/s12991-014-0027-x"},{"key":"45","doi-asserted-by":"crossref","unstructured":"46. Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, Desnick RJ. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med. 2005; 142:439-450.","DOI":"10.7326\/0003-4819-142-6-200503150-00010"},{"key":"46","doi-asserted-by":"crossref","unstructured":"47. Stein P, Badminton M, Barth J, Rees D, Stewart MF; British and Irish Porphyria Network. Best practice guidelines on clinical management of acute attacks of porphyria and their complications. Ann Clin Biochem. 2013; 50:217-223.","DOI":"10.1177\/0004563212474555"},{"key":"47","doi-asserted-by":"crossref","unstructured":"48. Lin CS, Park SB, Krishnan AV. Porphyric neuropathy. Handb Clin Neurol. 2013; 115:613-627.","DOI":"10.1016\/B978-0-444-52902-2.00036-9"},{"key":"48","doi-asserted-by":"crossref","unstructured":"49. Albers JW, Robertson WC Jr, Daube JR. Electrodiagnostic findings in acute porphyric neuropathy. Muscle Nerve. 1978; 1:292-296.","DOI":"10.1002\/mus.880010405"},{"key":"49","doi-asserted-by":"crossref","unstructured":"50. Fl\u00fcgel KA, Druschky KF. Electromyogram and nerve conduction in patients with acute intermittent porphyria. J Neurol. 1977; 214:267-279.","DOI":"10.1007\/BF00316572"},{"key":"50","doi-asserted-by":"crossref","unstructured":"51. Cavanagh JB, Mellick RS. On the nature of the peripheral nerve lesions associated with acute intermittent porphyria. J Neurol Neurosurg Psychiatry. 1965; 28:320-327.","DOI":"10.1136\/jnnp.28.4.320"},{"key":"51","doi-asserted-by":"crossref","unstructured":"52. Albers JW, Fink JK. Porphyric neuropathy. Muscle Nerve. 2004; 30:410-422.","DOI":"10.1002\/mus.20137"},{"key":"52","doi-asserted-by":"crossref","unstructured":"53. Wu CL, Ro LS, Jung SM, Tsai TC, Chu CC, Lyu RK, Huang CC, Kuo HC. Clinical presentation and electrophysiological findings of porphyric neuropathies: a follow-up study. Muscle Nerve. 2015; 51:363-369.","DOI":"10.1002\/mus.24327"},{"key":"53","doi-asserted-by":"crossref","unstructured":"54. Simon NG, Herkes GK. The neurologic manifestations of the acute porphyrias. J Clin Neurosci. 2011; 18:1147-1153.","DOI":"10.1016\/j.jocn.2011.01.003"},{"key":"54","doi-asserted-by":"crossref","unstructured":"55. Lin CS, Lee MJ, Park SB, Kiernan MC. Purple pigments: the pathophysiology of acute porphyric neuropathy. Clin Neurophysiol. 2011; 122:2336-2344.","DOI":"10.1016\/j.clinph.2011.07.036"},{"key":"55","doi-asserted-by":"crossref","unstructured":"56. Hift RJ, Meissner PN. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: Evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. Medicine (Baltimore). 2005; 84:48-60.","DOI":"10.1097\/01.md.0000152454.56435.f3"},{"key":"56","doi-asserted-by":"crossref","unstructured":"57. Gonz\u00e1lez-Arriaza HL, Bostwick JM. Acute porphyrias: a case report and review. Am J Psychiatry. 2003; 160:450-459.","DOI":"10.1176\/appi.ajp.160.3.450"},{"key":"57","doi-asserted-by":"crossref","unstructured":"58. Santosh PJ, Malhotra S. Varied psychiatric manifestations of acute intermittent porphyria. Biol Psychiatry. 1994: 36:744-747.","DOI":"10.1016\/0006-3223(94)90085-X"},{"key":"58","doi-asserted-by":"crossref","unstructured":"59. Alshammary S, Dulaijan RA, Saleh K, Zakaria H, Eldamati A, Alwakeel N, Al-Mulhim A. Acute intermittent porphyria after right hemi-colectomy. Int J Surg Case Rep. 2017; 40:116-119.","DOI":"10.1016\/j.ijscr.2017.09.018"},{"key":"59","doi-asserted-by":"crossref","unstructured":"60. Dos Santos AR, De Albuquerque RR, Doriqui MJ, Costa GC, Dos Santos AP. Biochemical and hematological analysis in acute intermittent porphyria (AIP): a case report. An Acad Bras Cienc. 2013; 85:1207-1214.","DOI":"10.1590\/S0001-37652013000300019"},{"key":"60","doi-asserted-by":"crossref","unstructured":"61. Holroyd S, Seward RL. Psychotropic drugs in acute intermittent porphyria. Clin Pharmacol Ther. 1999; 66:323-325.","DOI":"10.1016\/S0009-9236(99)70041-X"},{"key":"61","doi-asserted-by":"crossref","unstructured":"62. Regan L, Gonsalves L, Tesar G. Acute intermittent porphyria. Psychosomatics. 1999; 40:521-523.","DOI":"10.1016\/S0033-3182(99)71193-X"},{"key":"62","doi-asserted-by":"crossref","unstructured":"63. Tay JL, Lal M. Clinical characteristic of psychiatric symptoms in acute intermittent porphyria (AIP): a report of a pair of identical twins. Asian J Psychiatr. 2017; 29:192-193.","DOI":"10.1016\/j.ajp.2017.07.023"},{"key":"63","doi-asserted-by":"crossref","unstructured":"64. Cederl\u00f6f M, Bergen SE, Larsson H, Land\u00e9n M, Lichtenstein P. Acute intermittent porphyria: comorbidity and shared familial risks with schizophrenia and bipolar disorder in Sweden. Br J Psychiatry. 2015; 207:556-557.","DOI":"10.1192\/bjp.bp.114.157073"},{"key":"64","doi-asserted-by":"crossref","unstructured":"65. Millward LM, Kelly P, King A, Peters TJ. Anxiety and depression in the acute porphyrias. J Inherit Metab Dis. 2005; 28:1099-1107.","DOI":"10.1007\/s10545-005-4561-1"},{"key":"65","doi-asserted-by":"crossref","unstructured":"66. Bylesj\u00f6 I, Wikberg A, Andersson C. Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study. Scand J Clin Lab Invest. 2009; 69:612-618.","DOI":"10.1080\/00365510902935979"},{"key":"66","doi-asserted-by":"crossref","unstructured":"67. Patience DA, Blackwood DH, McColl KE, Moore MR. Acute intermittent porphyria and mental illness \u2013 a family study. Acta Psychiatr Scand. 1994; 89:262-267.","DOI":"10.1111\/j.1600-0447.1994.tb01511.x"},{"key":"67","doi-asserted-by":"crossref","unstructured":"68. Tishler PV, Woodward B, O&apos;Connor J, Holbrook DA, Seidman LJ, Hallett M, Knighton DJ. High prevalence of intermittent acute porphyria in a psychiatric patient population. Am J Psychiatry. 1985; 142:1430-1436.","DOI":"10.1176\/ajp.142.12.1430"},{"key":"68","unstructured":"69. Ottosson JO, Perris C. Screening for porphyria among psychiatric patients. Acta Psychiatr Scand Suppl. 1971; 221:128-132."},{"key":"69","doi-asserted-by":"crossref","unstructured":"70. Sanders AR, Rincon-Limas DE, Chakraborty R, Grandchamp B, Hamilton JD, Fann WE, Patel PI. Association between genetic variation at the porphobilinogen deaminase gene and schizophrenia. Schizophr Res. 1993; 8:211-221.","DOI":"10.1016\/0920-9964(93)90019-F"},{"key":"70","doi-asserted-by":"crossref","unstructured":"71. Owen MJ, Mant R, Parfitt E, <i>et al<\/i>. No association between RFLPs at the porphobilinogen deaminase gene and schizophrenia. Hum Genet. 1992; 90:131-132.","DOI":"10.1007\/BF00210756"},{"key":"71","doi-asserted-by":"crossref","unstructured":"72. Berger S, Stattmann M, Cicvaric A, Monje FJ, Coiro P, Hotka M, Ricken G, Hainfellner J, Greber-Platzer S, Yasuda M, Desnick RJ, Pollak DD. Severe hydroxymethylbilane synthase deficiency causes depression-like behavior and mitochondrial dysfunction in a mouse model of homozygous dominant acute intermittent porphyria. Acta Neuropathol Commun. 2020; 8:38.","DOI":"10.1186\/s40478-020-00910-z"},{"key":"72","doi-asserted-by":"crossref","unstructured":"73. Lithner F, Wetterberg L. Hepatocellular carcinoma in patients with acute intermittent porphyria. Acta Med Scand. 1984; 215:271-274.","DOI":"10.1111\/j.0954-6820.1984.tb05005.x"},{"key":"73","doi-asserted-by":"crossref","unstructured":"74. Kauppinen R, Mustajoki P. Acute hepatic porphyria and hepatocellular carcinoma. Br J Cancer. 1988; 57:117-120.","DOI":"10.1038\/bjc.1988.23"},{"key":"74","doi-asserted-by":"crossref","unstructured":"75. Andant C, Puy H, Bogard C, Faivre J, Soul\u00e9 JC, Nordmann Y, Deybach JC. Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol. 2000; 32:933-939.","DOI":"10.1016\/S0168-8278(00)80097-5"},{"key":"75","doi-asserted-by":"crossref","unstructured":"76. Innala E, Andersson C. Screening for hepatocellular carcinoma in acute intermittent porphyria: a 15-year follow-up in northern Sweden. J Intern Med. 2011; 269:538-545.","DOI":"10.1111\/j.1365-2796.2010.02335.x"},{"key":"76","doi-asserted-by":"crossref","unstructured":"77. Sardh E, Wahlin S, Bj\u00f6rnstedt M, Harper P, Andersson DE. High risk of primary liver cancer in a cohort of 179 patients with acute hepatic porphyria. J Inherit Metab Dis. 2013; 36:1063-1071.","DOI":"10.1007\/s10545-012-9576-9"},{"key":"77","doi-asserted-by":"crossref","unstructured":"78. Andersson C, Bjersing L, Lithner F. The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria. J Intern Med. 1996; 240:195-201.","DOI":"10.1046\/j.1365-2796.1996.21847000.x"},{"key":"78","doi-asserted-by":"crossref","unstructured":"79. Schneider-Yin X, van Tuyll van Serooskerken AM, Went P, Tyblewski W, Poblete-Guti\u00e9rrez P, Minder EI, Frank J. Hepatocellular carcinoma in variegate porphyria: a serious complication. Acta Derm Venereol. 2010; 90:512-515.","DOI":"10.2340\/00015555-0870"},{"key":"79","doi-asserted-by":"crossref","unstructured":"80. Schneider-Yin X, van Tuyll van Serooskerken AM, Siegesmund M, <i>et al<\/i>. Biallelic inactivation of protoporphyrinogen oxidase and hydroxymethylbilane synthase is associated with liver cancer in acute porphyrias. J Hepatol. 2015; 62:734-738.","DOI":"10.1016\/j.jhep.2014.11.029"},{"key":"80","doi-asserted-by":"crossref","unstructured":"81. Karim Z, Lyoumi S, Nicolas G, Deybach JC, Gouya L, Puy H. Porphyrias: a 2015 update. Clin Res Hepatol Gastroenterol. 2015; 39:412-425.","DOI":"10.1016\/j.clinre.2015.05.009"},{"key":"81","doi-asserted-by":"crossref","unstructured":"82. Laafi J, Homedan C, Jacques C, Gueguen N, Schmitt C, Puy H, Reynier P, Carmen Martinez M, Malthi\u00e8ry Y. Pro-oxidant effect of ALA is implicated in mitochondrial dysfunction of HepG2 cells. Biochimie. 2014; 106:157-166.","DOI":"10.1016\/j.biochi.2014.08.014"},{"key":"82","doi-asserted-by":"crossref","unstructured":"83. Lee JM, Lee WH, Kay HY, Kim ES, Moon A, Kim SG. Hemin, an iron-binding porphyrin, inhibits HIF-1alpha induction through its binding with heat shock protein 90. Int J Cancer. 2012; 130:716-727.","DOI":"10.1002\/ijc.26075"},{"key":"83","doi-asserted-by":"crossref","unstructured":"84. Park JH, Lee CK, Hwang YS, Park KK, Chung WY. Hemin inhibits cyclooxygenase-2 expression through nuclear factor-kappa B activation and ornithine decarboxylase expression in 12-O-tetradecanoylphorbol-13-acetate-treated mouse skin. Mutat Res. 2008; 642:68-73.","DOI":"10.1016\/j.mrfmmm.2008.04.004"},{"key":"84","doi-asserted-by":"crossref","unstructured":"85. Chung WY, Lee JM, Lee WY, Surh YJ, Park KK. Protective effects of hemin and tetrakis(4-benzoic Acid)porphyrin on bacterial mutagenesis and mouse skin carcinogenesis induced by 7, 12-dimethylbenz[a] anthracene. Mutat Res. 2000; 472:139-145.","DOI":"10.1016\/S1383-5718(00)00137-6"},{"key":"85","doi-asserted-by":"crossref","unstructured":"86. Hayatsu H, Sugiyama C, Arimoto-Kobayashi S, Negishi T. Porphyrins as possible preventers of heterocyclic amine carcinogenesis. Cancer Lett. 1999; 143:185-187.","DOI":"10.1016\/S0304-3835(99)00122-6"},{"key":"86","doi-asserted-by":"crossref","unstructured":"87. Balwani M, Wang B, Anderson KE, Bloomer JR, Bissell DM, Bonkovsky HL, Phillips JD, Desnick RJ; Porphyrias Consortium of the Rare Diseases Clinical Research Network. Acute hepatic porphyrias: recommendations for evaluation and long-term management. Hepatology. 2017; 66:1314-1322.","DOI":"10.1002\/hep.29313"},{"key":"87","doi-asserted-by":"crossref","unstructured":"88. Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. N Engl J Med. 2017; 377:862-872.","DOI":"10.1056\/NEJMra1608634"},{"key":"88","doi-asserted-by":"crossref","unstructured":"89. Besur S, Schmeltzer P, Bonkovsky HL. Acute Porphyrias. J Emerg Med. 2015; 49:305-312.","DOI":"10.1016\/j.jemermed.2015.04.034"},{"key":"89","doi-asserted-by":"crossref","unstructured":"90. Stewart MF. Review of hepatocellular cancer, hypertension and renal impairment as late complications of acute porphyria and recommendations for patient follow-up. J Clin Pathol. 2012; 65:976-980.","DOI":"10.1136\/jclinpath-2012-200791"},{"key":"90","doi-asserted-by":"crossref","unstructured":"91. Anderson KE. Acute hepatic porphyrias: current diagnosis &amp; management. Mol Genet Metab. 2019; 128:219-227.","DOI":"10.1016\/j.ymgme.2019.07.002"},{"key":"91","doi-asserted-by":"crossref","unstructured":"92. Unzu C, Sampedro A, Sardh E, Maule\u00f3n I, Enr\u00edquez de Salamanca R, Prieto J, Salido E, Harper P, Fontanellas A. Renal failure affects the enzymatic activities of the three first steps in hepatic heme biosynthesis in the acute intermittent porphyria mouse. PLoS One. 2012; 7:e32978.","DOI":"10.1371\/journal.pone.0032978"},{"key":"92","doi-asserted-by":"crossref","unstructured":"93. Kong XF, Han Y, Li XH, Gao DY, Zhang XX, Gong QM. Recurrent porphyria attacks in a Chinese patient with a heterozygous PBGD mutation. Gene. 2013; 524:401-402.","DOI":"10.1016\/j.gene.2013.03.130"},{"key":"93","doi-asserted-by":"crossref","unstructured":"94. Messas N, Willemain R, Bilger A, Rondeau-Lutz M, Kuhnert C, Mertes PM, Morel O, Collange O. Takotsubo syndrome triggered by acute intermittent porphyria attack: an unusual stressor for catecholamine-induced cardiomyopathy. Int J Cardiol. 2016; 207:28-30.","DOI":"10.1016\/j.ijcard.2016.01.035"},{"key":"94","doi-asserted-by":"crossref","unstructured":"95. Pallet N, Mami I, Schmitt C, Karim Z, Fran\u00e7ois A, Rabant M, Nochy D, Gouya L, Deybach JC, Xu-Dubois Y, Thervet E, Puy H, Karras A. High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria. Kidney Int. 2015; 88:386-395.","DOI":"10.1038\/ki.2015.97"},{"key":"95","doi-asserted-by":"crossref","unstructured":"96. Andersson C, Wikberg A, Stegmayr B, Lithner F. Renal symptomatology in patients with acute intermittent porphyria. A population-based study. J Intern Med. 2000; 248:319-325.","DOI":"10.1046\/j.1365-2796.2000.00743.x"},{"key":"96","unstructured":"97. Mydl\u00edk M, Derzsiov\u00e1 K. Kidney damage in acute intermittent porphyria. Przegl Lek. 2011; 68:610-613."},{"key":"97","doi-asserted-by":"crossref","unstructured":"98. Marsden JT, Chowdhury P, Wang J, Deacon A, Dutt N, Peters TJ, Macdougall IC. Acute intermittent porphyria and chronic renal failure. Clin Nephrol. 2008; 69:339-346.","DOI":"10.5414\/CNP69339"},{"key":"98","doi-asserted-by":"crossref","unstructured":"99. Andersson C, Lithner F. Hypertension and renal disease in patients with acute intermittent porphyria. J Intern Med. 1994; 236:169-175.","DOI":"10.1111\/j.1365-2796.1994.tb01279.x"},{"key":"99","doi-asserted-by":"crossref","unstructured":"100. DeFrancisco M, Savino PJ, Schatz NJ. Optic atrophy in acute intermittent porphyria. Am J Ophthalmol. 1979; 87:221-224.","DOI":"10.1016\/0002-9394(79)90147-8"},{"key":"100","doi-asserted-by":"crossref","unstructured":"101. Wolter JR, Clark RL, Kallet HA. Ocular involvement in acute intermittent porphyria. Am J Ophthalmol. 1972; 74:666-674.","DOI":"10.1016\/0002-9394(72)90828-8"},{"key":"101","doi-asserted-by":"crossref","unstructured":"102. Tchernitchko D, Tavernier Q, Lamoril J, Schmitt C, Talbi N, Lyoumi S, Robreau AM, Karim Z, Gouya L, Thervet E, Karras A, Puy H, Pallet N. A variant of peptide transporter 2 predicts the severity of porphyria-associated kidney disease. J Am Soc Nephrol. 2017; 28:1924-1932.","DOI":"10.1681\/ASN.2016080918"},{"key":"102","doi-asserted-by":"crossref","unstructured":"103. Dhar GJ, Bossenmaier I, Cardinal R, Petryka ZJ, Watson CJ. Transitory renal failure following rapid administration of a relatively large amount of hematin in a patient with acute intermittent porphyria in clinical remission. Acta Med Scand. 1978; 203:437-443.","DOI":"10.1111\/j.0954-6820.1978.tb14903.x"},{"key":"103","doi-asserted-by":"crossref","unstructured":"104. Labbe RF, Talman EL, Aldrich RA. Porphyrin metabolism. II. Uric acid excretion in experimental porphyria. Biochim Biophys Acta. 1954; 15:590-591.","DOI":"10.1016\/0006-3002(54)90024-4"},{"key":"104","doi-asserted-by":"crossref","unstructured":"105. Fern\u00e1ndez-Miranda C, De La Calle M, Larumbe S, G\u00f3mez-Izquierdo T, Porres A, G\u00f3mez-Gerique J, Enr\u00edquez de Salamanca R. Lipoprotein abnormalities in patients with asymptomatic acute porphyria. Clin Chim Acta. 2000; 294:37-43.","DOI":"10.1016\/S0009-8981(99)00257-0"},{"key":"105","doi-asserted-by":"crossref","unstructured":"106. Lees RS, Song CS, Levere RD, Kappas A. Hyperbeta-lipoproteinemia in acute intermittent porphyria. Preliminary Report. N Engl J Med. 1970; 282:432-433.","DOI":"10.1056\/NEJM197002192820807"},{"key":"106","doi-asserted-by":"crossref","unstructured":"107. De Block CE, Leeuw IH, Gaal LF. Premenstrual attacks of acute intermittent porphyria: hormonal and metabolic aspects \u2013 a case report. Eur J Endocrinol. 1999; 141:50-54.","DOI":"10.1530\/eje.0.1410050"},{"key":"107","doi-asserted-by":"crossref","unstructured":"108. Kaplan PW, Lewis DV. Juvenile acute intermittent porphyria with hypercholesterolemia and epilepsy: a case report and review of the literature. J Child Neurol. 1986; 1:38-45.","DOI":"10.1177\/088307388600100106"},{"key":"108","doi-asserted-by":"crossref","unstructured":"109. Mann JG, DeNardo GL. Acute intermittent porphyria associated with hyperthyroidism. J Clin Endocrinol Metab. 1965; 25:1151-1155.","DOI":"10.1210\/jcem-25-9-1151"}],"container-title":["Intractable &amp; Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/9\/4\/9_2020.03054\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T03:43:10Z","timestamp":1604720590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/9\/4\/9_2020.03054\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,31]]},"references-count":108,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2020.03054","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"value":"2186-361X","type":"electronic"},{"value":"2186-3644","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,31]]}}}